EuroNet-PHL-LP1:儿童低危结节性淋巴细胞为主型霍奇金淋巴瘤完全切除或低剂量化疗
EuroNet-PHL-LP1 是一项前瞻性 3 期试验,纳入 18 岁以下 IA/IIA 期结节性淋巴细胞为主型霍奇金淋巴瘤患者,评估完全切除后主动监测或 3 周期不含蒽环类的 CVP 化疗。完全切除组 5 年 EFS/PFS 为 79.5%;CVP 队列 1 中达完全代谢缓解者 5 年 PFS 为 91.3%。该策略成为 EuroNet-PHL 早期 nLPHL 的标准治疗。
要点
- 完全切除后主动监测的 5 年 EFS/PFS 为 79.5%。
- CVP 化疗后达完全代谢缓解者 5 年 PFS 为 91.3%。
- CVP 期间 68.3% 患者发生 3-4 级中性粒细胞减少,无治疗相关死亡。
核心结论
- 完全切除后以及低强度、不含蒽环类化疗后达完全代谢缓解的患者获得了优异结局。
- 该策略现构成 EuroNet-PHL 对早期 nLPHL 的标准治疗。
研究设计与样本
- EuroNet-PHL-LP1 为前瞻性 3 期试验,注册号 EudraCT 2007-004092-19。
- 纳入年龄 <18 岁、IA/IIA 期 nLPHL 患者,共注册 267 例,可评估 247 例。
- 完全切除者进入主动监测;不可切除者接受 3 周期 CVP 化疗。
- CVP 队列 1 需 18F-FDG PET 阴性方可停止治疗;2014 年修正后 CVP 队列 2 省略 PET,仅用 CT 和/或 MRI 定义缓解。
- 主要终点为 5 年 EFS,死亡、复发、第二恶性肿瘤和 PET 阳性计为事件;CVP 队列 2 以 PFS 为主要终点。
主要发现
- CVP 队列 1 中 51/82(62%)达完全代谢缓解(CMR),5 年 EFS 为 56.4%,CMR 组 5 年 PFS 为 91.3%。
- CVP 队列 2 中 84 例患者 5 年 PFS 为 64.7%。
- CVP 期间 68.3% 患者发生 3-4 级中性粒细胞减少,未报告治疗相关死亡。
- 切除后复发的 18 例患者中 6 例重新进入 CVP 组。
关键数值与推荐
- 完全切除后主动监测的 5 年 EFS/PFS 为 79.5%。
- CVP 队列 1 中 CMR 组 5 年 PFS 为 91.3%,总体 5 年 EFS 为 56.4%。
- CVP 队列 2 的 5 年 PFS 为 64.7%。
- CVP 期间 3-4 级中性粒细胞减少发生率为 68.3%。
临床怎么用
- 早期 nLPHL 患者可考虑完全切除后主动监测。
- 不可切除者接受 3 周期不含蒽环类的 CVP 化疗,化疗后达 CMR 者预后优异。
- 该策略已成为 EuroNet-PHL 早期 nLPHL 的标准治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Children and adolescents with early-stage nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL) have a 5-year event-free survival (EFS) of ∼77% after complete lymph node resection and ∼89% with anthracycline-containing chemotherapy. We investigated whether those patients can be successfully treated with surgical resection alone or with low-intensity, anthracycline-free CVP (cyclophosphamide, vinblastine, and prednisone) chemotherapy. EuroNet-PHL-LP1 was a prospective phase 3 trial enrolling patients aged <18 years with stage IA/IIA nLPHL. Complete resection led to active surveillance. Patients with unresectable disease received 3 cycles CVP. In CVP cohort 1, treatment cessation required negative 2-deoxy-2-[fluorine-18]fluoro-d-glucose positron emission tomography (18F-FDG PET). An amendment in 2014 omitted PET for end-of-treatment response; computed tomography and/or magnetic resonance imaging alone defined response in CVP cohort 2. The primary endpoint was 5-year EFS, with death, relapse, second malignancy, and PET positivity counting as events; for CVP cohort 2, progression-free survival (PFS) was primary. Among 267 registered patients, 247 were evaluable. Seventy-eight underwent resection only; their 5-year EFS/PFS was 79.5%. Six of 18 patients who relapsed after surgical resection reentered the CVP arm. In CVP cohort 1, 51 of 82 (62%) achieved complete metabolic response (CMR). Five-year EFS was 56.4%, whereas 5-year PFS in the CMR group was 91.3%. In contrast, PFS in 84 patients in CVP cohort 2 was 64.7%. During CVP, 68.3% of patients experienced grade 3 to 4 neutropenia. No treatment-related deaths were reported. Excellent outcomes were achieved after complete resection and with low-intensity, anthracycline-free chemotherapy if in CMR after chemotherapy. This strategy now constitutes the EuroNet-PHL standard of care for early-stage nLPHL. The trial was registered at www.clinicaltrialsregister.eu as EudraCT 2007-004092-19.
引用
- Shankar A, Landman-Parker J, Mascarin M, et al. EuroNet-PHL-LP1: complete resection or low-dose chemotherapy for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv. 2026. PMID: 42234940. doi:10.1182/bloodadvances.2026019765
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。